Rentschler Appoints New Chief Business Officer
News Mar 08, 2013
Rentschler Biotechnologie GmbH has announced the appointment of Frank Ternes to the position of Chief Business Officer effective February 1, 2013.
In this position, Mr. Ternes will contribute to the success of the organization by leading the planning, development and execution of all business development, sales & marketing and project management activities.
"Mr. Ternes is an excellent addition to Rentschler's management board," says Dr. Nikolaus F. Rentschler, CEO and owner of Rentschler.
Dr. Rentschler continued, "With his broad experience in the contract manufacturing business, he has a keen understanding of technology, a strong customer focus, and a proven track record for achieving success.”
Frank Ternes brings more than 25 years of experience from Operations and Technology at Boehringer Ingelheim where he last served as Senior Vice President of Biopharmaceutical Contract Manufacturing.
Mr. Ternes holds a degree equivalent to a master’s degree in economics from the University of Bonn, Germany.
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018